Through this study, we demonstrate the significance of MEG3/EZH2/SIRT6 axis in NAFLD development and provide new therapeutic targets for the treatment of NAFLD. This evidence concerns the gene SIRT6 and metabolic dysfunction-associated steatotic liver disease.